Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
SXTP
$3.06
$
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
Next Earnings
2026-02-25
Beta
2.959
Average Volume
Market Cap
Last Dividend
CIK
0001946563
ISIN
US83006G5009
CUSIP
83006G401
CEO
Geoffrey Stuart Dow
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
3
IPO Date
2023-07-12
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Analyzing Rafael (NYSE:RFL) & 60 Degrees Pharmaceuticals (NASDAQ:SXTP) | Rafael (NYSE: RFL - Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ: SXTP - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation. Profitability This table compares Rafael and 60 | Defense World | 2026-02-20 03:03:05 |
| 60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership | GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine) Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company's marketing strategy Partnership will improve the affordability of ARAKODA at over 70,000 pharmacies nationwide for people planning travel to malaria-endemic regions WASHINGTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced a partnership with GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., to offer eligible consumers savings of up to 30% on ARAKODA® (tafenoquine). ARAKODA is the only FDA-approved, broad spectrum, once-weekly prescription malaria prevention on the U.S. market. | GlobeNewsWire | 2026-02-02 08:01:00 |
| 60 Degrees Pharmaceuticals (NASDAQ:SXTP) Shares to Reverse Split on Tuesday, January 20th | 60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) shares are set to reverse split on the morning of Tuesday, January 20th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, January 19th. 60 Degrees Pharmaceuticals Trading Down 2.4% SXTP stock opened | Defense World | 2026-01-16 01:19:00 |
| 60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio | WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it will effect a one-for-four (1:4) reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on January 20, 2026, at 12:01 AM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). 60 Degrees Pharma has requested that its Common Stock begin trading on January 20, 2026, on a post-reverse split basis on the Nasdaq under the existing symbol "SXTP". | GlobeNewsWire | 2026-01-15 08:01:00 |
| 60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State | Peer-reviewed NC State study found Babesia in 24% of chronic fatigue patients, supporting further study of chronic babesiosis and ARAKODA® evaluation. | GlobeNewsWire | 2025-12-29 08:01:00 |
| Here's Why 60 Degrees Pharmaceuticals Inc. (SXTP) Looks Ripe for Bottom Fishing | 60 Degrees Pharmaceuticals Inc. (SXTP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. | Zacks Investment Research | 2025-12-23 10:56:05 |
| 60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026 | 60 Degrees Pharmaceuticals will expand ARAKODA sales in 2026 with more reps, a GoodRx partnership, enhanced digital marketing, and added babesiosis trials | GlobeNewsWire | 2025-12-11 08:01:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-02-12 | 2026-02-12 | View Filing |
| 8-K | 2026-01-23 | 2026-01-23 | View Filing |
| 8-K | 2026-01-21 | 2026-01-21 | View Filing |
| 8-K | 2026-01-08 | 2026-01-08 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-12 | 2025-12-12 | View Filing |
| SC 13G/A | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| SC 13G/A | 2025-11-07 | 2025-11-07 | View Filing |
| SC 13G/A | 2025-11-07 | 2025-11-07 | View Filing |
| 8-K | 2025-10-10 | 2025-10-10 | View Filing |
| 4 | 2025-09-15 | 2025-09-15 | View Filing |
| 8-K | 2025-09-09 | 2025-09-09 | View Filing |
| 424B5 | 2025-09-05 | 2025-09-05 | View Filing |
| 8-K | 2025-09-05 | 2025-09-05 | View Filing |
| DEFR14A | 2025-09-02 | 2025-08-29 | View Filing |
| DEF 14A | 2025-08-27 | 2025-08-26 | View Filing |
| PRE 14A | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-14 | 2025-08-14 | View Filing |
| 4 | 2025-08-14 | 2025-08-14 | View Filing |
| 3 | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-13 | 2025-08-13 | View Filing |
| SC 13G | 2025-07-22 | 2025-07-22 | View Filing |
| SC 13G | 2025-07-18 | 2025-07-18 | View Filing |
| 8-K | 2025-07-18 | 2025-07-18 | View Filing |
| SC 13G/A | 2025-07-17 | 2025-07-17 | View Filing |
| SC 13G | 2025-07-17 | 2025-07-17 | View Filing |
| 424B4 | 2025-07-16 | 2025-07-16 | View Filing |
| EFFECT | 2025-07-16 | 2025-07-16 | View Filing |
| S-1 | 2025-07-07 | 2025-07-07 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 4 | 2025-06-05 | 2025-06-05 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| 10-Q | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-04-09 | 2025-04-09 | View Filing |
| EFFECT | 2025-04-03 | 2025-04-03 | View Filing |
| S-1/A | 2025-03-27 | 2025-03-27 | View Filing |
| 10-K | 2025-03-27 | 2025-03-27 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| S-1 | 2025-02-14 | 2025-02-14 | View Filing |
| D | 2025-02-12 | 2025-02-11 | View Filing |
| D | 2025-02-11 | 2025-02-11 | View Filing |
| SC 13G | 2025-02-11 | 2025-02-11 | View Filing |
| 8-K | 2025-02-06 | 2025-02-06 | View Filing |
| 424B5 | 2025-02-06 | 2025-02-06 | View Filing |
| SC 13G | 2025-02-03 | 2025-02-03 | View Filing |
| 8-K | 2025-01-30 | 2025-01-30 | View Filing |
| 424B5 | 2025-01-30 | 2025-01-30 | View Filing |
| 8-K | 2025-01-28 | 2025-01-28 | View Filing |
| 4 | 2025-01-24 | 2025-01-24 | View Filing |
| 4 | 2025-01-24 | 2025-01-24 | View Filing |
| 4 | 2025-01-21 | 2025-01-21 | View Filing |
| 4 | 2025-01-21 | 2025-01-21 | View Filing |
| 8-K | 2025-01-08 | 2025-01-08 | View Filing |
| 4 | 2024-12-18 | 2024-12-18 | View Filing |
| 4 | 2024-12-09 | 2024-12-09 | View Filing |
| 4 | 2024-11-21 | 2024-11-21 | View Filing |
| SC 13G | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-13 | 2024-11-13 | View Filing |
| 8-K | 2024-11-06 | 2024-11-06 | View Filing |
| DEF 14A | 2024-10-15 | 2024-10-15 | View Filing |
| 8-K | 2024-10-08 | 2024-10-08 | View Filing |
| PRE 14A | 2024-10-02 | 2024-10-02 | View Filing |
| EFFECT | 2024-10-01 | 2024-10-01 | View Filing |
| S-3 | 2024-09-19 | 2024-09-19 | View Filing |
| 4 | 2024-09-11 | 2024-09-11 | View Filing |
| 8-K | 2024-09-06 | 2024-09-06 | View Filing |
| 8-K | 2024-08-28 | 2024-08-28 | View Filing |
| 8-K | 2024-08-14 | 2024-08-14 | View Filing |
| 10-Q | 2024-08-14 | 2024-08-14 | View Filing |
| 8-K | 2024-08-12 | 2024-08-12 | View Filing |
| 424B5 | 2024-08-02 | 2024-08-02 | View Filing |
| 8-K | 2024-07-26 | 2024-07-26 | View Filing |
| 424B5 | 2024-07-26 | 2024-07-26 | View Filing |
| 424B5 | 2024-07-24 | 2024-07-24 | View Filing |
| 424B5 | 2024-07-22 | 2024-07-22 | View Filing |
| EFFECT | 2024-07-19 | 2024-07-19 | View Filing |
| 8-K | 2024-07-16 | 2024-07-16 | View Filing |
| S-3 | 2024-07-12 | 2024-07-12 | View Filing |
| 8-K | 2024-06-27 | 2024-06-27 | View Filing |
| 8-K | 2024-06-12 | 2024-06-12 | View Filing |
| DEF 14A | 2024-05-30 | 2024-05-30 | View Filing |
| 4 | 2024-05-21 | 2024-05-21 | View Filing |
| 4 | 2024-05-21 | 2024-05-21 | View Filing |
| 4 | 2024-05-21 | 2024-05-21 | View Filing |
| 4 | 2024-05-21 | 2024-05-21 | View Filing |
| 4 | 2024-05-21 | 2024-05-21 | View Filing |
| 4 | 2024-05-21 | 2024-05-21 | View Filing |
| 10-Q | 2024-05-15 | 2024-05-15 | View Filing |
| SC 13G/A | 2024-05-07 | 2024-05-07 | View Filing |
| PRE 14A | 2024-05-03 | 2024-05-03 | View Filing |
| 8-K | 2024-05-02 | 2024-05-02 | View Filing |
| 4 | 2024-04-03 | 2024-04-03 | View Filing |
| 10-K | 2024-04-01 | 2024-04-01 | View Filing |
| 8-K | 2024-03-15 | 2024-03-14 | View Filing |
| 8-K | 2024-02-28 | 2024-02-27 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| MACD | 137.85% | 0.94 | 14 | 0.69 | 2.17 | 126.27 |
| Keltner Channel Strategy | 131.92% | 0.42 | 25 | 0.44 | 0.79 | 120.33 |
| Williams PercentR Strategy | 95.59% | 1.31 | 19 | 0.37 | 0.61 | 84 |
| xxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | x |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | x |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | x | xxxxx | xxxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |